About 23andMe
Industry:
Consumer Genomics/Drug Discovery
Founded:
2006
Founders:
Anne Wojcicki, Linda Avey, Paul Cusenza
Status:
Public (NASDAQ: ME)
Funding & Growth
Total Raised:
$1B+
Valuation:
$500M+ market cap
Stage:
Public
Key Investors:
Google
GSK
Sequoia Capital
✓ Pros
- • Massive genetic database (14M+)
- • Drug discovery partnerships
- • Bay Area location
- • Consumer and therapeutic arms
- • Interesting research opportunities
✗ Cons
- • Financial struggles
- • Recent layoffs and restructuring
- • Consumer genomics market saturation
- • Privacy concerns